METHYLERGONOVINE MALEATE

N/A

Manufactured by Lupin Pharmaceuticals,Inc.

1,362 FDA adverse event reports analyzed

Last updated: 2026-04-15

About METHYLERGONOVINE MALEATE

METHYLERGONOVINE MALEATE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Lupin Pharmaceuticals,Inc.. The most commonly reported adverse reactions for METHYLERGONOVINE MALEATE include WRONG DRUG ADMINISTERED, DRUG EXPOSURE DURING PREGNANCY, VOMITING, DYSPNOEA, HEADACHE. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for METHYLERGONOVINE MALEATE.

Top Adverse Reactions

WRONG DRUG ADMINISTERED68 reports
DRUG EXPOSURE DURING PREGNANCY51 reports
VOMITING46 reports
DYSPNOEA38 reports
HEADACHE37 reports
ABDOMINAL PAIN36 reports
NAUSEA35 reports
DRUG INEFFECTIVE31 reports
HAEMORRHAGE28 reports
DIZZINESS25 reports
PAIN24 reports
CYANOSIS23 reports
ACCIDENTAL EXPOSURE22 reports
MATERNAL EXPOSURE DURING PREGNANCY21 reports
HYPERTENSION20 reports
MEDICATION ERROR20 reports
BLOOD PRESSURE INCREASED18 reports
POSTPARTUM HAEMORRHAGE17 reports
CHEST PAIN16 reports
HYPOTENSION16 reports
PARAESTHESIA16 reports
ABORTION SPONTANEOUS15 reports
AGITATION15 reports
DISSEMINATED INTRAVASCULAR COAGULATION15 reports
LOSS OF CONSCIOUSNESS15 reports
OFF LABEL USE15 reports
UTERINE HAEMORRHAGE15 reports
ANXIETY14 reports
CAESAREAN SECTION14 reports
TACHYCARDIA14 reports
TREMOR14 reports
ACCIDENTAL DRUG INTAKE BY CHILD13 reports
MALAISE13 reports
CONVULSION12 reports
DEPRESSION12 reports
HYPOXIA12 reports
HYSTERECTOMY12 reports
SOMNOLENCE12 reports
APNOEA11 reports
ARTERIOSPASM CORONARY11 reports
CARDIAC ARREST11 reports
DRUG EXPOSURE VIA BREAST MILK11 reports
EXPOSURE DURING PREGNANCY11 reports
FATIGUE11 reports
HYPERHIDROSIS11 reports
MIGRAINE11 reports
PYREXIA11 reports
VAGINAL HAEMORRHAGE11 reports
ANAEMIA10 reports
BLOOD PRESSURE DECREASED10 reports
FEELING ABNORMAL10 reports
HYPOAESTHESIA10 reports
NORMAL NEWBORN10 reports
PERIPHERAL VASCULAR DISORDER10 reports
RASH10 reports
ABDOMINAL PAIN UPPER9 reports
BRADYCARDIA9 reports
COMA9 reports
DIARRHOEA9 reports
MYOCARDIAL INFARCTION9 reports
PAIN IN EXTREMITY9 reports
PALLOR9 reports
PRURITUS9 reports
VISION BLURRED9 reports
APPETITE DISORDER8 reports
ASTHENIA8 reports
CHILLS8 reports
DEPRESSED LEVEL OF CONSCIOUSNESS8 reports
FOETAL EXPOSURE DURING PREGNANCY8 reports
HEART RATE INCREASED8 reports
INJURY8 reports
IRRITABILITY8 reports
LETHARGY8 reports
NERVOUSNESS8 reports
OEDEMA PERIPHERAL8 reports
OLIGURIA8 reports
PULMONARY OEDEMA8 reports
RESTLESSNESS8 reports
UTERINE ATONY8 reports
VENTRICULAR HYPOKINESIA8 reports
ASPARTATE AMINOTRANSFERASE INCREASED7 reports
BLOOD CREATINE PHOSPHOKINASE INCREASED7 reports
CHEST DISCOMFORT7 reports
CHOLECYSTITIS CHRONIC7 reports
CIRCULATORY COLLAPSE7 reports
CONDITION AGGRAVATED7 reports
CRYING7 reports
ERGOT POISONING7 reports
MYALGIA7 reports
NO ADVERSE EVENT7 reports
OXYGEN SATURATION DECREASED7 reports
PULMONARY EMBOLISM7 reports
TOXICITY TO VARIOUS AGENTS7 reports
ABDOMINAL DISCOMFORT6 reports
ABORTION INDUCED6 reports
ALANINE AMINOTRANSFERASE INCREASED6 reports
BACK PAIN6 reports
CHOLELITHIASIS6 reports
COMPLETED SUICIDE6 reports
DECREASED APPETITE6 reports

Report Outcomes

Out of 608 classified reports for METHYLERGONOVINE MALEATE:

Serious 91.0%Non-Serious 9.0%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female475 (87.0%)
Male71 (13.0%)

Reports by Age

Age 3120 reports
Age 3418 reports
Age 2816 reports
Age 3516 reports
Age 3015 reports
Age 3215 reports
Age 2514 reports
Age 2914 reports
Age 2713 reports
Age 3713 reports
Age 3813 reports
Age 2412 reports
Age 3612 reports
Age 1810 reports
Age 59 reports
Age 419 reports
Age 228 reports
Age 238 reports
Age 408 reports
Age 27 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with METHYLERGONOVINE MALEATE?

This profile reflects 1,362 FDA FAERS reports that mention METHYLERGONOVINE MALEATE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for METHYLERGONOVINE MALEATE?

Frequently reported terms in FAERS include WRONG DRUG ADMINISTERED, DRUG EXPOSURE DURING PREGNANCY, VOMITING, DYSPNOEA, HEADACHE, ABDOMINAL PAIN. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures METHYLERGONOVINE MALEATE?

Labeling and FAERS entries often list Lupin Pharmaceuticals,Inc. in connection with METHYLERGONOVINE MALEATE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.